Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $30.65M rose 10.6% year over year, ahead of the +5.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.

Context

  • Selling, general & admin amounted to 39.4% of revenue in FY2025, down 23.7 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $215.72M (+86.1%) for the fiscal year ending Dec 2026, a step up from the +2.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.65M+2.2% QoQ
Last fiscal yearDec 2025
$115.9M+2.5% YoY
LTMMar 2026
$118.84M+5.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.6%+31.5%+20.9 pp
1 year+2.5%+86.1%+83.6 pp
3-year CAGR+1.0%+39.8%+38.8 pp
5-year CAGR+28.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
115.9M USD
Year-over-year change
+2.5%
4-year CAGR
+6.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 selling, general & admin of $118.84M is the 2nd highest of the 10 companies compared; the peer median is $34.4M.
  • Its year-over-year change of +5.8% is the 4th highest of 9, against a peer median of -1.1%.
  • Selling, general & admin amounts to 39.6% of revenue for RIGL, versus a peer median of 178.3%.
RIGL Competitors Peer median
Selling, General & Admin for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$533.92M +3.0%+4.1%21.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M +5.8%+1.0%39.6%
VSTMVerastem, Inc.LTM Mar 2026$88.42M +83.1%+48.1%178.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M +57.0%+11.6%11.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$52.28M -5.2%+10.5%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M -16.4%-5.4%98.7%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M -23.4%-6.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M -28.1%-0.2%3951.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$14.78M —-14.4%227.7%
CRDFCardiff Oncology, Inc.LTM Mar 2026$13.02M +27.1%+2.6%2479.6%
Peer median (excluding RIGL) $34.4M-1.1%+2.6%178.3%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.